f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Kaiser Permanente Joint Registry


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Terminated
Application Number /
Requirement Number		 P040023 / PAS004
Date Original Protocol Accepted 04/20/2010
Date Current Protocol Accepted 04/20/2010
Study Name Kaiser Permanente Joint Registry
Device Name DURALOC OPTION CERAMIC HIP SYSTEM
General Study Protocol Parameters
Study Design Prospective & Retrospective Study
Data Source External Registry
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives Registry study
Sample Size Kaiser has identified approximately 90 patients at multiple clinical sites in their total joint registry that have DURALOC Option ceramic on ceramic hip replacements.
Key Study Endpoints Depuy will provide the following information as the data exists and is permitted by Kaiser Permanente:

¿ Femoral Stem types
¿ The years in which the surgeries were performed
¿ Patient demographic summaries (age, gender, diagnosis, height, weight, BMI)
¿ Patient listing of reasons for revisions
¿ Revision rate
¿ Death rate
¿ Kaplan-Meier survival estimates
¿ Harris Hip Score over time
¿ Adverse Events
¿ Radiographic results
Follow-up Visits and Length of Follow-up The length of follow-up for this study is 5 years. Pending contract execution, Depuy will request that Kaiser recall these patients for annual follow-up visits.


Kaiser Permanente Joint Registry Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
1 year report 04/20/2011 04/21/2011 Overdue/Received
2 year report 07/03/2012 06/26/2012 On Time
3 year report 05/17/2013 05/30/2013 Overdue/Received


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-